Skip to content

US · CCM · MEDICAL - CARE FACILITIES

Concord Medical Services Holdings Limited (CCM) intrinsic value and stock valuation

$3.55as of 2026-11-21 · Mkt cap 706.23K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Concord Medical Services Holdings Limited DCF and intrinsic value

InvestorsCraft values CCM with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CCM’s statements →

Concord Medical Services Holdings Limited Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Care Facilities Beijing, NY 100020 concordmedical.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$460.5M+15.6% 5y CAGRd
20112025
Net income
-$-92.81M
20112025
Free cash flow
-$-293.16M
20112025
Total equity
$1.85B-5.1% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$460.5M$384M$537.4M$472.1M$485.6M
Operating income-$-239.33M-$-532.16M-$-462.99M-$-525.05M-$-458.32M
Net income-$-92.81M-$-308.24M-$-297.66M-$-489.66M-$-271.43M
EPSd-$-618.73M-$-2.05B-$-1.98B-$-3.26B-$-1.81B
Operating cash flow-$-201.82M-$-397.75M-$-276.47M-$-216.69M-$-359.31M
Capital expenditure-$-91.33M-$-410.83M-$-115.7M-$-383.77M-$-760.58M
Free cash flow-$-293.16M-$-808.58M-$-392.17M-$-600.47M-$-1.12B
Total assets$6.55B$6.73B$6.05B$6B$6.23B
Total debt$3.63B$3.93B$3.3B$3.24B$2.73B
Net debt$3.34B$3.71B$3.24B$3.08B$2.58B
Total equity$1.85B$1.62B$1.75B$2.02B$2.74B
Cash and short-term investments$297.8M$350.9M$58.1M$158.3M$157.4M
Income statement
20252024202320222021
Revenue$460.5M$384M$537.4M$472.1M$485.6M
Cost of revenue$434.7M$463.1M$614M$624.5M$542.5M
Gross profit$25.8M-$-79.16M-$-76.61M-$-152.41M-$-56.9M
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$265.2M$453M$386.4M$372.6M$401.4M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$265.2M$453M$386.4M$372.6M$401.4M
Cost and expenses$699.9M$916.1M$1B$997.1M$944M
Interest income$9.68M$14M$10.8M$10M$5.89M
Interest expense$152.3M$193.2M$165.7M$120.4M$73.8M
Depreciation and amortization$149.3M$130.8M$118.8M$123.2M$94.5M
Ebitda-$-71.77M-$-345.62M-$-344.16M-$-401.86M-$-363.86M
Operating income-$-239.33M-$-532.16M-$-462.99M-$-525.05M-$-458.32M
Total other income/expenses, net-$-134.02M-$-137.42M-$-92.61M-$-314.85M-$-70.92M
Income before tax-$-373.36M-$-669.58M-$-555.59M-$-839.9M-$-529.24M
Income tax expense$6.06M-$-17.5M-$-24.57M-$-70.91M-$-6.57M
Net income-$-92.81M-$-308.24M-$-297.66M-$-489.66M-$-271.43M
Weighted average shares outstanding$150K$150K$150K$150K$50K
Weighted average diluted shares outstanding$150K$150K$150K$150K$150K
Balance sheet
20252024202320222021
Cash and short-term investments$297.8M$350.9M$58.1M$158.3M$157.4M
Net receivables$44.1M$51.2M$73.5M$130.3M$383M
Inventory$46M$33.4M$40.4M$84.8M$38.1M
Total current assets$941.9M$984M$617.2M$759.8M$584.5M
Property, plant and equipment, net$3.97B$4.01B$4.13B$3.45B$3.35B
Goodwill and intangible assets$1.21B$1.25B$898.7M$1.34B$1.66B
Long-term investments$422M$472.2M$394.7M$437.9M$390.6M
Total non-current assets$5.61B$5.74B$5.44B$5.25B$5.65B
Total assets$6.55B$6.73B$6.05B$6B$6.23B
Accounts payable$119.3M$199.4M$129.2M$146.8M$102.5M
Short-term debt$1.02B$1.08B$1.09B$548.5M$319.8M
Deferred revenue$95.7M$46.2M$59.4M$100.8M$81M
Total current liabilities$1.95B$2.13B$1.95B$1.12B$804.5M
Long-term debt$2.61B$2.85B$2.21B$2.69B$2.41B
Deferred revenue, non-current$0.00$0.00$44.5M$0.00$0.00
Total non-current liabilities$2.74B$2.98B$2.36B$2.87B$2.68B
Capital lease obligations$168.4M$184.3M$239.5M$235.9M$234.7M
Total liabilities$4.7B$5.11B$4.31B$3.99B$3.49B
Common stock$100K$100K$100K$100K$100K
Retained earnings-$-4.47B-$-4.37B-$-4.06B-$-3.77B-$-3.28B
Accumulated other comprehensive income (loss)-$-75.56M-$-77.35M-$-65.42M-$-27.77M-$-29.5M
Total equity$1.85B$1.62B$1.75B$2.02B$2.74B
Total investments$422M$606.8M$394.7M$437.9M$390.6M
Total debt$3.63B$3.93B$3.3B$3.24B$2.73B
Net debt$3.34B$3.71B$3.24B$3.08B$2.58B
Cash flow statement
20252024202320222021
Net income-$-379.42M-$-652.08M-$-297.66M-$-489.66M-$-271.43M
Depreciation and amortization$149.3M$130.8M$128.5M$132.8M$104.1M
Stock-based compensation$0.00$0.00$0.00-$-5.92M$14.7M
Change in working capital-$-97.84M-$-149.33M-$-14.49M-$-60.16M-$-115.74M
Accounts receivable$6.14M$12M$36.5M$640K-$-64.45M
Inventory-$-12.58M$6.5M$44.5M-$-46.75M-$-4.35M
Accounts payable-$-122.29M$93.1M$0.00$0.00$0.00
Net cash provided by operating activities-$-201.82M-$-397.75M-$-276.47M-$-216.69M-$-359.31M
Investments in property, plant and equipment-$-91.3M-$-400.67M-$-115.7M-$-383.77M-$-760.58M
Acquisitions, net-$-10K-$-92.94M$0.00$0.00$1.57M
Net cash used for investing activities$54M-$-593.44M-$-47.68M-$-118.79M-$-565.98M
Common stock issued$0.00$510.5M$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$197.2M$1.15B$257.7M$383.1M$642.5M
Net change in cash$61.7M$146.6M-$-68.92M$430K-$-287.48M
Cash at end of period$298.7M$237M$90.4M$159.3M$158.9M
Operating cash flow-$-201.82M-$-397.75M-$-276.47M-$-216.69M-$-359.31M
Capital expenditure-$-91.33M-$-410.83M-$-115.7M-$-383.77M-$-760.58M
Free cash flow-$-293.16M-$-808.58M-$-392.17M-$-600.47M-$-1.12B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Concord Medical Services Holdings Limited

        Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People’s Republic of China. It operates in two segments, Network and Hospital. The company’s services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, China.

        CEO
        Jianyu Yang
        Employees
        610
        Beta
        -0.96

        Explore

        Frequently asked questions

        What is the intrinsic value of Concord Medical Services Holdings Limited (CCM)?

        InvestorsCraft does not currently publish an intrinsic value for CCM. How the IC value is calculated.

        Is CCM undervalued?

        InvestorsCraft does not publish an undervaluation signal for CCM at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.